Thyroidectomy-specific Enhanced Recovery After Surgery (ERAS) Protocol

May 7, 2026 updated by: Mohamed I Omar, Assiut University

A Comprehensive Enhanced Recovery After Surgery (ERAS) Protocol for Thyroidectomy

Thyroidectomy is generally considered a low-to-moderate risk operation; however, postoperative pain, nausea/vomiting, and prolonged hospital stays remain common issues. Enhanced Recovery After Surgery (ERAS) pathways aim to optimize perioperative care and accelerate recovery. This study evaluates the effectiveness and safety of a standardized ERAS pathway in patients undergoing elective thyroidectomy. The prospective ERAS cohort is compared with a historical control group receiving conventional care to assess the impact on the length of hospital stay, postoperative pain, opioid consumption, and complication rates.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

143

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Asyut Governorate
      • Asyut, Asyut Governorate, Egypt, 71516
        • Surgical Oncology Department, South Egypt Cancer Institute, Assiut University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients scheduled for elective thyroidectomy for benign or malignant disease at a tertiary cancer institute

Description

Inclusion Criteria:

  • Patients aged 18-75 years
  • ASA physical status I-III.
  • Scheduled for elective thyroidectomy for benign or malignant disease.

Exclusion Criteria:

  • Re-operative thyroid surgery
  • Concomitant neck dissection
  • Inability to comply with the ERAS pathway

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ERAS group
A prospective cohort undergoing elective thyroidectomy under an ERAS protocol.
Procedure: Enhanced Recovery After Surgery protocol
This incorporates standardized preoperative counseling, reduced fasting, multimodal opioid-sparing analgesia, total intravenous anesthesia, selective drain use, early oral intake and mobilization, and PTH-guided calcium supplementation
Other Names:
  • ERAS
Control group
A historical control cohort undergoing thyroidectomy under conventional care during the 12 months preceding ERAS implementation
Procedure: Conventional perioperative care
This often involves prolonged preoperative fasting, opioid-based analgesia, and delayed mobilization

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of hospital stay
Time Frame: Up to 30 days post-surgery
Hours from surgery end to discharge
Up to 30 days post-surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total opioid consumption
Time Frame: Within first 24 hours
Oral Morphine Milligram Equivalents (MME)
Within first 24 hours
Postoperative nausea and vomiting (PONV)
Time Frame: Up to 24 hours postoperatively
Incidence of PONV
Up to 24 hours postoperatively
Rate of postoperative hypocalcemia
Time Frame: First 30 days from the surgery
Biochemical and symptomatic occurrences
First 30 days from the surgery
30-day unplanned readmission rate
Time Frame: Up to 30 days postoperative
Number of unplanned readmissions
Up to 30 days postoperative
Postoperative pain scores
Time Frame: Assessed in the first 24 hours postoperatively
Mean Numeric Rating Scale (NRS-11; 0 = no pain to 10 = worst imaginable pain) at rest in 24 hours. NRS scores are categorized as mild (1-3), moderate (4-6), or severe (7-10).
Assessed in the first 24 hours postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2024

Primary Completion (Actual)

May 31, 2025

Study Completion (Actual)

May 31, 2025

Study Registration Dates

First Submitted

May 2, 2026

First Submitted That Met QC Criteria

May 2, 2026

First Posted (Actual)

May 8, 2026

Study Record Updates

Last Update Posted (Actual)

May 12, 2026

Last Update Submitted That Met QC Criteria

May 7, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • M.I.Omar-ERAS26

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thyroid Diseases

Clinical Trials on Enhanced Recovery After Surgery protocol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe